Population Pharmacokinetics, Efficacy, and Safety of Moxetumomab Pasudotox in Patients With Relapsed or Refractory Hairy Cell Leukemia.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY(2020)
摘要
Aims To characterize the pharmacokinetics (PK) of moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin, in adults with relapsed or refractory hairy cell leukaemia, we examined data from a phase 1 study (Study 1001;n= 49) and from the pivotal clinical study (Study 1053;n= 74). Methods Data from both studies were pooled (n= 123) to develop a population PK model. Covariates included demographics, disease state, liver and kidney function, prior treatment, and antidrug antibodies (ADAs). Exposure-response and exposure-safety were analysed separately by study. A 1-compartment model with linear elimination from the central compartment and 2 clearance (CL) rates was developed. Results Moxetumomab pasudotox was cleared more rapidly after cycle 1, day 1 (CL1= 24.7 L/h) than subsequently (CL2= 3.76 L/h), with high interindividual variability (116 and 109%, respectively). In Study 1053, patients with ADA titres >10 240 showed ~4-fold increase in CL. Higher exposures (>= median) were related to higher response rates, capillary leak syndrome and increased creatinine (Study 1053 only), or grade >= 3 adverse events (Study 1001 only). Clinical benefits were still observed in patients with lower exposure or high ADA titres. Conclusion Despite a high incidence of immunogenicity with increased clearance, moxetumomab pasudotox demonstrated efficacy in hairy cell leukaemia.
更多查看译文
关键词
cancer,modelling and simulation,pharmacokinetic-pharmacodynamic,pharmacokinetics
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要